301 related articles for article (PubMed ID: 31394558)
1. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?
Soura E; Gagari E; Stratigos A
Curr Opin Oncol; 2019 Sep; 31(5):461-468. PubMed ID: 31394558
[TBL] [Abstract][Full Text] [Related]
2. Medical treatment of advanced cutaneous squamous-cell carcinoma.
Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for advanced cutaneous squamous cell carcinoma.
Fitzgerald K; Tsai KK
Semin Cutan Med Surg; 2019 Mar; 38(1):E67-E74. PubMed ID: 31051028
[TBL] [Abstract][Full Text] [Related]
5. Challenges and new perspectives in the treatment of advanced cutaneous squamous cell carcinoma.
Brancaccio G; Moscarella E; Briatico G; Verolino P; Alfano R; Argenziano G
Minerva Med; 2020 Dec; 111(6):589-600. PubMed ID: 32955822
[TBL] [Abstract][Full Text] [Related]
6. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
Benzaquen M
Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
[TBL] [Abstract][Full Text] [Related]
7. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
9. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
10. Treatment approaches of advanced cutaneous squamous cell carcinoma.
Peris K; Piccerillo A; Del Regno L; Di Stefani A
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():19-22. PubMed ID: 34855254
[TBL] [Abstract][Full Text] [Related]
11. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.
Ogata D; Tsuchida T
Curr Treat Options Oncol; 2019 Mar; 20(4):30. PubMed ID: 30874952
[TBL] [Abstract][Full Text] [Related]
12. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.
Burton KA; Ashack KA; Khachemoune A
Am J Clin Dermatol; 2016 Oct; 17(5):491-508. PubMed ID: 27358187
[TBL] [Abstract][Full Text] [Related]
14. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Hernández-Guerrero T; Doger B; Moreno V
Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
Giri A; Bauman JR
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous squamous cell carcinoma: state of the art, perspectives and unmet needs.
Heppt MV; Leiter U
J Dtsch Dermatol Ges; 2023 Apr; 21(4):421-424. PubMed ID: 36999577
[TBL] [Abstract][Full Text] [Related]
17. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M
Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510
[TBL] [Abstract][Full Text] [Related]
18. Update of advanced cutaneous squamous cell carcinoma.
de Jong E; Lammerts MUPA; Genders RE; Bouwes Bavinck JN
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1(Suppl 1):6-10. PubMed ID: 34855246
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
Que SKT; Zwald FO; Schmults CD
J Am Acad Dermatol; 2018 Feb; 78(2):249-261. PubMed ID: 29332705
[TBL] [Abstract][Full Text] [Related]
20. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]